A multinational study distinguishing Alzheimer's and healthy patients using cerebrospinal fluid tau/Aβ42 cutoff with concordance to amyloid positron emission tomography imaging.

Yi Mo, Julie Stromswold,Kimberly Wilson,Daniel Holder,Cyrille Sur,Omar Laterza,Mary J Savage,Arie Struyk,Philip Scheltens,Charlotte E Teunissen,James Burke,S Lance Macaulay,Geir Bråthen,Sigrid Botne Sando,Linda R White, Christy Weiss, Arturo Cowes, Michele M Bush, Ganga DeSilva,David G Darby,Stephanie R Rainey-Smith, Jackie Surls, Eileen Sagini,Michael Tanen, Amy Altman, Johan Luthman,Michael F Egan

Alzheimer's & Dementia: Diagnosis, Assessment & Disease Monitoring（2017）

引用 23|浏览40

暂无评分

摘要

A tau/Aβ42 cutoff with acceptable sensitivity and specificity distinguished HC from mild-to-moderate AD subjects and maximized concordance to brain amyloidosis. The defined cutoff demonstrated that CSF analysis may be useful as a surrogate to imaging assessment of AD pathology.

查看译文

关键词

Alzheimer's disease,Diagnostic test assessment,PET,Amyloid β42,Tau

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要